Walter M. Stadler to Vascular Endothelial Growth Factor Receptor-1
This is a "connection" page, showing publications Walter M. Stadler has written about Vascular Endothelial Growth Factor Receptor-1.
Connection Strength
0.017
-
Phase I dose escalation and pharmacokinetic study of AZD2171, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinase, in patients with hormone refractory prostate cancer (HRPC). Invest New Drugs. 2007 Oct; 25(5):445-51.
Score: 0.017